X4 reports positive Phase 2 mavorixafor data: ANC normalized, G-CSF reduced 70% in chronic neutropenia

X4 Pharmaceuticals, Inc

Mavorixafor monotherapy durably increased mean ANC to normal levels at Month 3 (n=9) and Month 6 (n=8).
Severe CN patients achieved >2-fold mean ANC increase over 6 months (n=4).
G-CSF dose reduced in 9/12 eligible patients; mean reduction 52% at Month 3, 70% at Month 6 with normal ANC.
Neutrophil functionality sub-study: mean % functional neutrophils comparable to healthy donors after 6 months.
No drug-related serious adverse events; mavorixafor generally well tolerated as monotherapy and combination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.